Inclusion Criteria:  All Chronic hepatitis C patients to be treated with the DAAs approved by CFDA/NMPA Age≥18 years  Exclusion Criteria:  Patients experienced with DAAs Documented HCC, AFP>500ng/ml Unlikely to survive 1 year or inability to participate and follow up for the study period